Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H13F3N2 |
Molecular Weight | 230.2295 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C1=CC=CC(=C1)N2CCNCC2
InChI
InChIKey=KKIMDKMETPPURN-UHFFFAOYSA-N
InChI=1S/C11H13F3N2/c12-11(13,14)9-2-1-3-10(8-9)16-6-4-15-5-7-16/h1-3,8,15H,4-7H2
Trifluoromethylphenylpiperazine (TFMPP) acts on serotonin receptors 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A and 5-HT2C and functions as a full agonist at all sites except the 5-HT2A receptor, where it acts as a weak partial agonist or antagonist. In addition, TFMPP binds to the sodium-dependent serotonin transporter, SERT and evokes the release of serotonin. Besides was shown, that the N-Benzylpiperazine/TFMPP combination produced effects, which crudely mimic those of MDMA, commonly known as ecstasy. The neurophysiological effects of TFMPP in humans was also studied and was shown that TFMPP may affect transmitter systems involved in speeding of interhemispheric communication in the male brain.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P08908 Gene ID: 3350.0 Gene Symbol: HTR1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15496938 |
288.0 nM [Ki] | ||
Target ID: P28222 Gene ID: 3351.0 Gene Symbol: HTR1B Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15496938 |
132.0 nM [Ki] | ||
Target ID: P28221 Gene ID: 3352.0 Gene Symbol: HTR1D Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15496938 |
282.0 nM [Ki] | ||
Target ID: P28223 Gene ID: 3356.0 Gene Symbol: HTR2A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15496938 |
269.0 nM [Ki] | ||
Target ID: P28335 Gene ID: 3358.0 Gene Symbol: HTR2C Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15496938 |
62.0 nM [Ki] | ||
Target ID: P31645 Gene ID: 6532.0 Gene Symbol: SLC6A4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15496938 |
121.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20924753
Healthy, right-handed males (age: 25 ± 5.6 years) were given placebo (n = 15) or TFMPP (0.94 mg/kg, oral, n = 15) and tested both pre- and 2 h post-drug administration
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27358233
It was investigated the cytotoxic effects of mixtures of N-Benzylpiperazine (BZP) and 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in vitro. Human-derived HepaRG cells and primary rat hepatocytes were exposed to the drugs, individually or combined at different mixture ratios, and cytotoxicity was assessed by the MTT assay. It was observed that primary rat hepatocytes are more sensitive than HepaRG cells to the toxicity of BZP (EC50 2.20 and 6.60 mM, respectively) and TFMPP (EC50 0.14 and 0.45 mM, respectively). For all BZP-TFMPP combinations tested, CA was the most appropriate model to predict the mixture effects. TFMPP proved to act additively with BZP to produce significant hepatotoxicity (p < 0.01).
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-Trifluoromethylphenylpiperazine
Created by
admin on Fri Dec 15 17:58:40 GMT 2023 , Edited by admin on Fri Dec 15 17:58:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
83536
Created by
admin on Fri Dec 15 17:58:40 GMT 2023 , Edited by admin on Fri Dec 15 17:58:40 GMT 2023
|
PRIMARY | |||
|
DTXSID10165876
Created by
admin on Fri Dec 15 17:58:40 GMT 2023 , Edited by admin on Fri Dec 15 17:58:40 GMT 2023
|
PRIMARY | |||
|
15532-75-9
Created by
admin on Fri Dec 15 17:58:40 GMT 2023 , Edited by admin on Fri Dec 15 17:58:40 GMT 2023
|
PRIMARY | |||
|
239-574-4
Created by
admin on Fri Dec 15 17:58:40 GMT 2023 , Edited by admin on Fri Dec 15 17:58:40 GMT 2023
|
PRIMARY | |||
|
128882
Created by
admin on Fri Dec 15 17:58:40 GMT 2023 , Edited by admin on Fri Dec 15 17:58:40 GMT 2023
|
PRIMARY | |||
|
4296
Created by
admin on Fri Dec 15 17:58:40 GMT 2023 , Edited by admin on Fri Dec 15 17:58:40 GMT 2023
|
PRIMARY | |||
|
TRIFLUOROMETHYLPHENYLPIPERAZINE
Created by
admin on Fri Dec 15 17:58:40 GMT 2023 , Edited by admin on Fri Dec 15 17:58:40 GMT 2023
|
PRIMARY | |||
|
C018406
Created by
admin on Fri Dec 15 17:58:40 GMT 2023 , Edited by admin on Fri Dec 15 17:58:40 GMT 2023
|
PRIMARY | |||
|
25R3ONU51C
Created by
admin on Fri Dec 15 17:58:40 GMT 2023 , Edited by admin on Fri Dec 15 17:58:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE)
SALT/SOLVATE (PARENT)